WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Moderator

Ann Marie Navar, MD, PhD

Associate Professor, Departments of Internal Medicine and Population and Data Sciences
Member, Division of Cardiology
UT Southwestern Medical Center
Dallas, Texas, United States

Disclosures

Ann Marie Navar, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Bayer; Boehringer Ingelheim; Cerner; Janssen; Lilly; New Amsterdam Pharma; Novartis; Novo Nordisk; Pfizer
Research funding from: Amgen; Bristol Myers Squibb; Esperion; Janssen

Faculty

Christie M. Ballantyne, MD, FACP, FACC

Professor of Medicine
Chief, Section of Cardiology
Chief, Section of Cardiovascular Research
Baylor College of Medicine
Houston, Texas, United States

Disclosures

Christie M. Ballantyne, MD, FACP, FACC, has the following relevant financial relationships:
Consultant or advisor for: 89 bio; Abbott Diagnostics; Alnylam Pharmaceuticals; Althera; Amarin; Amgen; Arrowhead Pharmaceuticals; AstraZeneca; Denka Seiken; Esperion; Genentech; Gilead Sciences; Illumina; Matinas BioPharma, Inc.; Merck; New Amsterdam Pharma; Novartis; Novo Nordisk; Pfizer; Regeneron; Roche Diagnostic
Research funding from: Abbott Diagnostics; Akcea; Amgen; Arrowhead Pharmaceuticals; Esperion; Ionis; Merck; Novartis; Novo Nordisk; Regeneron; Roche Diagnostic

Raul D. Santos, MD, PhD

Associate Professor and Director Lipid Clinic Heart Institute (InCor)
University of Sao Paulo Medical School Hospital
Researcher, Hospital Israelita Albert Einstein
Past President, International Atherosclerosis Society
Sao Paulo, Brazil

Disclosures

Raul D. Santos, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Abbott; Aché; Amgen; Amryt Pharma; AstraZeneca; Hypera Pharma; Libbs; Novartis; Novo Nordisk; Pfizer; PTC Therapeutics; Sanofi
Speaker or member of speakers bureau for: Abbott; Aché; Amgen; AstraZeneca; Biolab; EMS; Getz Pharma; Hypera Pharma; Libbs; Merck; Novartis; Novo Nordisk; Pfizer; PTC Therapeutics; Sanofi
Contracted researcher for: Amgen; Esperion; Kowa; Novartis; Sanofi

Editor

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Anne M. Sendaydiego, PharmD, has no relevant financial relationships.

Compliance Reviewer

Susan L. Smith, MN, PhD

Associate Director, Accreditation and Compliance

Disclosures

Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

From Medscape Education

Complex Clinical Cases for Specialists: Getting Patients to Target LDL-C Despite Barriers

Authors: Moderator Ann Marie Navar, MD, PhD; Faculty Christie M. Ballantyne, MD, FACP, FACC, and Raul D. Santos, MD, PhDFaculty and Disclosures

processing....

Posted: 12/09/2022

This educational activity is intended for an international audience of non-US cardiologists, primary care physicians, diabetes specialists and endocrinologists, and nephrologists.

The goal of this activity is for the learner to be better able to appropriately use lipid-lowering therapy (LLT) to achieve low-density lipoprotein cholesterol (LDL-C) targets and maintain long-term medication adherence.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Guideline recommendations on lowering LDL-C in patients at high- and very-high-risk for atherosclerotic cardiovascular disease
Have greater competence related to
- Appropriate treatment of LDL-C dyslipidemia
- Selecting appropriate combination therapy strategies to achieve and maintain target LDL-C level

Educational Impact Challenge

The goal of this activity is for the learner to be better able to appropriately use lipid-lowering therapy (LLT) to achieve low-density lipoprotein-cholesterol (LDL-C) targets and maintain adherence for the long-term.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 7

Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

Ann Marie Navar, MD, PhD

Faculty

Christie M. Ballantyne, MD, FACP, FACC

Raul D. Santos, MD, PhD

Editor

Anne M. Sendaydiego, PharmD

Compliance Reviewer

Susan L. Smith, MN, PhD

Peer Reviewer

Complex Clinical Cases for Specialists: Getting Patients to Target LDL-C Despite Barriers

Educational Impact Challenge